This Article Full Text Full Text (PDF) All Versions of this Article: 39/8/2280    most recent STROKEAHA.107.505354v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montaner, J. Articles by Alvarez-Sabín, J. Search for Related Content PubMed PubMed Citation Articles by Montaner, J. Articles by Alvarez-Sabín, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Related Collections Other diagnostic testing Acute Stroke Syndromes Embolic stroke Transient Ischemic Attacks

(Stroke. 2008;39:2280.)
© 2008 American Heart Association, Inc.

Original Contributions

Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers

Joan Montaner, MD, PhD; Mila Perea-Gainza, MD; Pilar Delgado, MD, PhD; Marc Ribó, MD, PhD; Pilar Chacón, MD, PhD; Anna Rosell, PhD; Manolo Quintana; Mauricio E. Palacios, MD; Carlos A. Molina, MD, PhD José Alvarez-Sabín, MD, PhD

From the Neurovascular Research Laboratory, Neurovascular Unit, Neurology Department, Vall d'Hebron Hospital, Barcelona, Spain.

Correspondence to Dr Joan Montaner, Neurovascular Research Lab, Institut de Recerca, Hospital Vall d'Hebron, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain. E-mail 31862jmv{at}comb.es

Background and Purpose— Because there is no biologic marker offering precise information about stroke etiology, many patients receive a diagnosis of undetermined stroke even after all available diagnostic tests are done, precluding correct treatment.

Methods— To examine the diagnostic value of a panel of biochemical markers to differentiate stroke etiologies, consecutive acute stroke patients were prospectively evaluated. Brain computed tomography, ultrasonography, cardiac evaluations, and other tests were done to identify an etiologic diagnosis according to TOAST classification. Blood samples were drawn on Emergency Department arrival (<24 hours) to test selected biomarkers: C-reactive protein, D-dimer, soluble receptor for advanced glycation end products, matrix metalloproteinase-9, S-100b, brain natriuretic peptide (BNP), neurotrophin-3, caspase-3, chimerin, and secretagogin (assayed by ELISA).

Results— Of 707 ischemic stroke patients included, 36.6% were cardioembolic, 21.4% atherothrombotic, 18.1% lacunar, and 23.9% of undetermined origin. High levels of BNP, soluble receptor for advanced glycation end products, and D-dimer (P<0.0001) were observed in patients with cardioembolic stroke. Independent predictors (odds ratios with CIs are given) of cardioembolic stroke were as follows: atrial fibrillation 15.3 (8.4–27.7, P<0.001); other embolic cardiopathies 14.7 (4.7–46, P<0.001); total anterior circulation infarction 4 (2.3–6.8, P<0.001); BNP >76 pg/mL 2.3 (1.4–3.7, P=0.001); and D-dimer >0.96 µg/mL 2.2 (1.4–3.7, P=0.001). Even among patients with transient symptoms (n=155), a high BNP level identified cardioembolic etiology (6.7, 2.4–18.9; P<0.001). A model combining clinical and biochemical data had a sensitivity of 66.5% and a specificity of 91.3% for predicting cardioembolism.

Conclusions— Using a combination of biomarkers may be a feasible strategy to improve the diagnosis of cardioembolic stroke in the acute phase, thus rapidly guiding other diagnostic tests and accelerating the start of optimal secondary prevention.

Key Words: atherosclerosis • cerebral ischemia • natriuretic peptides • embolism • D-dimer • stroke

This article has been cited by other articles:

				W. Whiteley, W. L. Chong, A. Sengupta, and P. Sandercock Blood Markers for the Prognosis of Ischemic Stroke: A Systematic Review Stroke, May 1, 2009; 40(5): e380 - e389. [Abstract] [Full Text] [PDF]